The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Clinical Evaluation of $^{57}Co-labelled$ Bleomycin for Tumor Localization

$^{57}Co-BLM$을 이용한 종양진단 신티그라피에 관한 연구

  • Ryu, Young-Wun (Laboratory of Nuclear Medicine, Korea Cancer Center Hospital) ;
  • Kim, Jang-Hee (Laboratory of Nuclear Medicine, Korea Cancer Center Hospital) ;
  • Lee, Jhin-Oh (Laboratory of Nuclear Medicine, Korea Cancer Center Hospital)
  • 유용운 (원자력병원 핵의학연구실) ;
  • 김장휘 (원자력병원 핵의학연구실) ;
  • 이진오 (원자력병원 핵의학연구실)
  • Published : 1987.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Investigation with $^{57}Co-Bleomycin$ in patients with the various cancers and in tumor bearing animals are descirbed. In the patients, $^{57}Co-Bleomycin$ appears to be one of the useful tumor-seeking radiopharmaceuticals, and worth applicable to clinical uses. Labelled yield of $^{57}Co-Bleo$ was about 97 % by thin layer chromatography. The pyrogen free tests were performed to meet U.S.P. critical ranges. In clinical studies with $^{57}Co-Bleo$, 4 cases out of 5 patients with lung cancer., 2 cases among 3 thyroid cancer patients, and all 3 hepatoma patients showed positive tumor scans. The patients with stomach cancer, and the esophageal cancer showed false negative scintigraphy. A case with pulmonary tuberculosis showed a positive scan while liver abscess showed a negative picture. The merits of $^{57}Co-Bleomycin$ scintigraphy seems to be its relatively high affinity to tumors and low radiation hazard in spite of long physical half life.

Keywords